All In Biotech

Drug Trial Radar · NCT02430194

Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)

An Open-label, Dose-ranging, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Lonafarnib With Ritonavir-Boosting +/- Peginterferon Alfa-2a in Patients Chronically Infected With Delta Hepatitis (HDV) (LOWR-2)

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

55

Actual

Start

Dec 2014

Primary completion

Apr 18, 2017

Study completion Jun 15, 2017

Sponsor

Lead sponsor
EIT Pharma, Inc.Industry
Sponsor type
Industry
Collaborators
Ankara University
First posted
Apr 30, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An Open-label, Dose-ranging Study to Evaluate the Safety and Efficacy of Lonafarnib with Ritonavir Boosting +/- Peginterferon alfa-2a in Patients Chronically Infected with Delta Hepatitis (HDV) (LOWR-2).

Conditions

  • Chronic Hepatitis D Infection

Interventions

  • lonafarnibDrug

    antiviral farnesyl transferase inhibitor

  • ritonavirDrug

    CYP 3A4 inhibitor, lonafarnib booster

  • Pegylated interferon-alfa-2aDrug

    immunomodulator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ≥2 log10 Decline of HDV RNA From Baseline at End of Treatment (EOT)Time frame: 12-48 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ankara University Medical School

    Ankara, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.